|
Details
|
Specifications
|
|---|---|
|
CAS Number
|
2242751-53-5
|
|
Molecular Formula
|
C15H18ClFN2O3
|
|
Molecular Weight
|
328.77 g/mol.
|
|
Synonyms
|
Acoramidis Hydrochloride
|
|
Chemical Name
|
3-[3-(3,5-dimethyl-1H-pyrazol-4-yl) propoxy]-4-fluorobenzoic acid hydrochloride
|
|
Therapeutic use
|
Transthyretin (TTR) Stabilizer
|
|
Status
|
Tech pack available
|
|
Background
|
Acoramidis hydrochloride (brand name Attruby) is an oral, highly selective transthyretin (TTR) stabilizer approved by the FDA in Nov 2024 to treat transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM).
|
|
Grade
|
In house
|
|
Polymorph
|
Form A
|
|
Storage Temperature
|
Controlled room temperature (20?C ? 25?C)
|
Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*
Disclaimer:
The information provided on this webpage is based on the best available knowledge at the time of publication; however, accuracy and completeness are not guaranteed. Product specifications may change without notice. It is the responsibility of the purchaser or user to verify suitability and compliance. This product is intended for research use only and is not approved for human consumption.
Acoramidis hydrochloride (CAS 2242751-53-5) is an orally active, highly selective transthyretin (TTR) stabilizer developed for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). Approved by the US FDA in November 2024, acoramidis works by binding and stabilizing the TTR tetramer, mimicking a naturally protective genetic variant to prevent the tetramer from dissociating into the misfolded monomers that deposit as amyloid in cardiac tissue. By preserving TTR stability, it helps slow the progression of this serious, progressive cardiomyopathy.
With a molecular formula of C₁₅H₁₈ClFN₂O₃ and a molecular weight of 328.77 g/mol, acoramidis hydrochloride is a small-molecule benzoic acid derivative supplied in the crystalline Form A polymorph. As one of the newest approved therapies in the rapidly expanding ATTR-CM market, the molecule has driven strong global demand for reliable acoramidis hydrochloride manufacturers and suppliers across regulated and emerging markets.
As established API manufacturers in India, Shilpa Pharma Lifesciences supplies acoramidis hydrochloride as a bulk active pharmaceutical ingredient to pharmaceutical and biotechnology partners worldwide. Backed by a complete technical package and integrated CDMO services, Shilpa Pharma supports global partners from early development through commercial-scale manufacturing and supply.
Acoramidis hydrochloride is supplied as a drug substance (bulk API) for use by pharmaceutical and biotechnology manufacturers in the development and production of oral solid dosage forms for ATTR-CM. As an orally administered TTR stabilizer, the molecule binds at the thyroxine-binding sites of the transthyretin tetramer, increasing its kinetic stability and reducing the formation of amyloidogenic species that drive disease progression in both wild-type (ATTRwt) and hereditary, variant (ATTRv) forms of the condition.
In a development and manufacturing context, the API supports formulation and oral solid dosage (tablet) development, analytical method development and validation, impurity profiling and reference standard qualification, polymorph and stability studies, and scale-up to clinical and commercial supply. The defined crystalline Form A supplied by Shilpa Pharma supports consistent solid-state quality and reproducible processing during oral dosage form development.
As established acoramidis hydrochloride suppliers, Shilpa Pharma provides material exclusively to qualified pharmaceutical manufacturers, biotechnology companies, and international trading partners for development and manufacturing use under applicable regulatory frameworks.
In clinical use, acoramidis is generally well tolerated, with the most commonly reported adverse effects being gastrointestinal in nature, including diarrhoea and upper abdominal pain; these are typically mild. As acoramidis is used to manage a chronic cardiac condition, treatment is initiated and monitored by qualified clinicians in accordance with the approved product information, and dosing decisions rest with the prescribing physician.
From a handling and occupational-safety standpoint, acoramidis hydrochloride should be handled by trained personnel using appropriate engineering controls and personal protective equipment in accordance with the product’s Safety Data Sheet (SDS). The API should be stored at controlled room temperature (20°C to 25°C), protected from moisture and light, to maintain stability and quality.
This information is provided for scientific and technical reference to pharmaceutical professionals and does not constitute medical advice.
The cost of acoramidis hydrochloride varies according to order volume, required specifications, packaging, documentation, and delivery destination. As bulk API pricing is project- and quantity-specific, Shilpa Pharma does not publish standard list pricing for this product.
For current acoramidis hydrochloride pricing, bulk quantity cost estimates, and commercial supply terms, pharmaceutical and biotechnology buyers are invited to contact Shilpa Pharma directly. As trusted acoramidis hydrochloride suppliers and exporters, our team provides a tailored quotation based on your required quantity, grade, and regulatory documentation needs, along with competitive, cost-effective supply options for both development-scale and commercial-scale requirements.
Shilpa Pharma Lifesciences is one of the most trusted acoramidis hydrochloride manufacturers in India and a full-scale CDMO partner, supplying high-quality active pharmaceutical ingredients to pharmaceutical and biotech companies across more than 80 countries. For acoramidis hydrochloride, partners choose Shilpa Pharma for:
Partner with Shilpa Pharma, a trusted acoramidis hydrochloride manufacturer and exporter, for a dependable, scalable, and cost-effective global source of this API.
Happy Customers
Projects Successfully Completed
Established
PhD Experts Driving R&D Excellence
Team Size
World-Class API Manufacturing Sites
Global Audits Successfully Completed
Comprehensive CDMO Service Offerings
Everything You Need to Know About Shilpa Pharma
Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*
